| __timestamp | Ascendis Pharma A/S | Bristol-Myers Squibb Company |
|---|---|---|
| Wednesday, January 1, 2014 | 6274000 | 5699000000 |
| Thursday, January 1, 2015 | 9415000 | 5001000000 |
| Friday, January 1, 2016 | 11504000 | 5002000000 |
| Sunday, January 1, 2017 | 13482000 | 4849000000 |
| Monday, January 1, 2018 | 25057000 | 4551000000 |
| Tuesday, January 1, 2019 | 48473000 | 4871000000 |
| Wednesday, January 1, 2020 | 76669000 | 7661000000 |
| Friday, January 1, 2021 | 160180000 | 7690000000 |
| Saturday, January 1, 2022 | 221227000 | 7814000000 |
| Sunday, January 1, 2023 | 264410000 | 7772000000 |
| Monday, January 1, 2024 | 284545000 | 8414000000 |
In pursuit of knowledge
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Bristol-Myers Squibb Company and Ascendis Pharma A/S have taken different paths in optimizing these costs.
Bristol-Myers Squibb, a giant in the industry, has consistently maintained high SG&A expenses, peaking at approximately $7.8 billion in 2022. This reflects their expansive operations and significant market presence. However, their SG&A costs have shown a modest increase of about 37% from 2014 to 2023.
In contrast, Ascendis Pharma A/S, a smaller player, has seen a dramatic rise in SG&A expenses, skyrocketing by over 4,100% from 2014 to 2023. This surge indicates their aggressive expansion and investment in growth.
Understanding these trends offers valuable insights into how companies of different scales manage their operational costs in a dynamic market.
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
Bristol-Myers Squibb Company or Zoetis Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Bristol-Myers Squibb Company vs Supernus Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for United Therapeutics Corporation and Ascendis Pharma A/S
SG&A Efficiency Analysis: Comparing Viatris Inc. and Ascendis Pharma A/S
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Ascendis Pharma A/S
Who Optimizes SG&A Costs Better? Ascendis Pharma A/S or Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Ascendis Pharma A/S vs Dynavax Technologies Corporation
Comparing SG&A Expenses: Ascendis Pharma A/S vs Xencor, Inc. Trends and Insights